The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients  by Kaya, Akin et al.
The prognostic significance of vascular endothelial
growth factor levels in sera of non-small
cell lung cancer patients
Akin Kayaa,*, Aydin
-
Ciledaga, Banu Eris Gulbaya, Bari-s M. Poyraz
a,
Gokhan
-
Celika, Elif Sena, Hacer Savasb, Ismail Savasa
aDepartment of Chest Medicine, Ankara University School of Medicine, Ankara, Turkey
bDepartment of Biochemistry, Ankara Social Insurance State Hospital, Etlik, Ankara, Turkey
Received 24 June 2003; received in revised form 21 October 2003; accepted 17 December 2003
Summary Background: Angiogenesis, the formation of new blood vessels from the
existing vascular bed, is essential step for the growth and invasion of the primary
tumor. Vascular endothelial growth factor (VEGF) is known to play crucial role in
tumor angiogenesis. Increased serum VEGF levels may be associated with poor
prognosis in patients with non-small cell lung cancer (NSCLC).
Methodology: In the present study, we measured plasma VEGF levels in 20 normal
subjects and 75 patients with untreated NSCLC; 23 operable (stages I, II, IIIA) and 52
inoperable (stages IIIB, IV) (Histology: squamous cell carcinoma, 40; adenocarcino-
ma, 27; undetermined, 8). VEGF was measured by enzyme-linked immunosorbent
assay.
Results : The median VEGF level in patient group was 119 pg/ml (29–1235), which
was significantly higher than the control group (P¼ 0.044). Median survival of
patients was 210 days (30–220). The patients were divided into high VEGF (4119 pg/
ml) and low VEGF (o119 pg/ml) groups using the median value as a cut-off. It was
investigated if there were significant associations between serum VEGF level and
clinico-pathological parameters like age, sex, histopathological diagnosis and TNM
staging. Also high VEGF and low VEGF patient groups were compared according to
the median survival.
Conclusions: Serum VEGF level is significantly associated with the clinical staging
of the patients (operable and inoperable) (P¼ 0.031) and it also correlates with the
prognosis of the patients (P¼ 0.0006).
& 2004 Elsevier Ltd. All rights reserved.
Introduction
It is well established that angiogenesis plays a
pivotal role in the growth of the neoplasm. It also
facilitates the progress and metastasis of tumor,
so the quantity of intratumoral neoangiogenesis
is related to prognosis. It was also shown that
there is strong correlation between density of
microvessels in the primary tumor and its meta-
static capability.1–7
Neoangiogenesis promotes the tumor progression
by delivering nutrients and oxygen which is
essential for growth, facilitating the penetration
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of tumor cells through the vessel wall and their
transport to distant organs and secreting growth
factors and cytokines from endothelial cells that
stimulate the tumor cells.2,4,8,9
The process of neovascularization is a complex
series of events including endothelial cell migra-
tion, proliferation, differentiation in addition to
extracellular matrix proteolysis.6,7 This process is
in equilibrium with stimulatory and inhibitory
factors.8
Tumor cells secrete a variety of stimulating
factors for microangiogenesis including fibroblast
growth factor, transforming growth factor, platelet
derived endothelial growth factor and hepatocyte
growth factor. Among these angiogenic factors,
Vascular endothelial growth (VEGF) is an endothe-
lial cell specific potent mitogen.6,7,9 It is a soluble
dimeric 34–46 kD protein involved in endothelial
cell proliferation and migration, increased vascular
permeability and stromal degradation through the
activation of proteolytic enzymes.4,5,8,9 VEGF ex-
pression has been demonstrated in some malignan-
cies including lung cancer and there are studies
that increased VEGF expression is correlated with
poor prognosis.8,9
Lung cancer is the leading cause of death among
malignancies and non-small cell lung cancer
(NSCLC) accounts for more than 75% of pulmonary
malignancies.8 NSCLC shows heterogenity for its
histopathological classification and behaviour. More
than half of the patients relapse after complete
resection, indicating that NSCLC is a disseminated
disease from the beginning in the majority of
patients. NSCLC prognosis is strongly influenced
by clinico-pathological parameters such as perfor-
mance status, tumor status, nodal metastatic
involvement and distant metastasis and yet the
TNM classification is the best predictor of outcome
for the patients.8,10 However, it is known that the
prognosis may vary considerably within each stage
of disease. Therefore, new prognostic factors must
be found to assess individual risk profiles.
It is thought that angiogenesis plays an important
role in NSCLC where distant organ metastasis
and regional nodal involvement is frequent.
VEGF expression has been reported in 50–95%
of NSCLC patients. Various investigators have
shown the correlation between VEGF expression
and poor prognosis, nodal metastasis and vessel
density.8,9,11,12
The exact origin of VEGF in sera of patients is still
unclear. It is thought that the malignant cells
themselves and inflammatory cells infiltrating
tumor are the main sources of VEGF as well as
peripheral blood cells like thrombocytes and
neutrophils.
There are few studies focussed on the levels of
VEGF in sera of lung cancer patients and its effect
on survival. In the present study, we aimed to
analyse the correlation between serum VEGF levels
in NSCLC patients and different clinico-pathological
parameters and prognosis.
Materials and methods
This study consisted of 20 healthy controls with
no known systemic disease, all matching with
age and sex with the patient group and 75
NSCLC patients. All subjects were enrolled in our
department between January 2001 and January
2002.
All patients were evaluated with a complete
physical examination and Karnofsky performance
scoring. Each patient underwent the following
staging procedures: chest radiography, chest com-
puted tomography (CT) scan, fibreoptic broncho-
scopy, radionuclide bone scan and abdominal
ultrasound. Cranial CT scanning was performed
only if the patient had neurological symptoms.
Patient samples were collected right after the
diagnosis and none of them have received any
therapy prior to sample collection.
After collection of the venous blood samples
from patients and control subjects, the samples
were centrifugated at 3000 rpm for 10min and
then stored at 701C. The serum samples were
assayed for the level of VEGF by a sandwich
enzyme-linked immunosorbent assay (ELISA), ac-
cording to the recommendation of the manufac-
turer with a human VEGF immunoassay kit
(Cytimmun Sciences Inc, Maryland, USA). Each
serum sample was assayed twice and minimum
detectable VEGF concentration was o18.6 pg/ml,
variation range coefficient was between 8.9% and
11.1%.
Statistical analysis
The Mann-Whitney U and w2-test were used to
compare different groups for continuous variables
and for cathegorical variables respectively.
Dates of diagnosis and death of all patients were
recorded. Overall survival was defined as the time
from the day of diagnosis to death; data on
survivors were accepted as the day the study was
ended. Overall survival was calculated using Ka-
plan-Meier Method. Survival curves were compared
with a log-rank test. Kruskal-Wallis test was used to
compare serum VEGF levels and tumor stage.
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All statistical analyses were performed using the
SPSS version 8.0 statistical program (SPSS Inc,
Chicago, Illinois, USA).
Results
Patient characteristics
In the NSCLC group median age was 62 (38–84) and
group consisted of 66 male (88%) and 9 female
(12%) patients.
Patient staging was made according to American
Joint Committee on Cancer. According to the
staging, at the time of diagnosis 23 patients
(30.7%) were operable (Stages I, II, IIIA) and 52
were inoperable (stages IIIB, IV). Majority of
patients (53.3%) had squamous cell carcinoma.
Patient characteristics were summarized in
Table 1.
Serum VEGF levels and patient
characteristics
In the patient group, median VEGF level was
119 pg/ml (29–1235 pg/ml). This was significantly
higher than the controls (P ¼ 0:044).
The patients were divided into high VEGF
(4119 pg/ml) and low VEGF (o119 pg/ml) groups
using the median value as a cut-off.
There were no significant associations between
serum VEGF levels and various clinico-pathological
parameters like age, sex and histopathology
(P40:05).
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Table 1 Patient characteristics.
Low VEGF group (p119) (38) High VEGF group (4119) (37) P ¼
Age
p62 22 18 40.05
462 16 19
Sex
Male 34 32 40.05
Female 4 5
Histopathology
Squamous cell 21 19 40.05
Adeno Ca 11 14
Undetermined 5 3
Large cell Ca 1 ()
Bronchooalveoler Ca () 1
Stage
IA 2 3 40.05
IB 5 1
IIA () ()
IIB 2 1
IIIA 7 3
IIIB 10 13
IV 12 17
Operable: 16 7 ¼ 0.031*
Inoperable: 22 30
Performance status
%10080 26 17 40.05
%7050 11 19
p%40 1 1
Median Survival 285 days (30–660 days) 150 days (30–510 days) ¼ 0.02*
Po0:05:
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According to the definitions in TNM staging
system, each T, N, M values were compared with
the serum VEGF levels. When the patients were
grouped as T1-2 and T3-4 according to the primary
tumor size, there was significant difference be-
tween these two groups for serum VEGF levels
(P ¼ 0:042). However, no significant association
were shown between serum VEGF levels and
presence of regional lymph node metastasis or
distant metastasis.
When patients were grouped as operable and
inoperable, there were statistically significant
difference between two groups for serum VEGF
levels (P ¼ 0:031) (Fig. 1). In the operable group
median serum VEGF level was 73 pg/ml (29.1–
614 pg/ml), while in the inoperable group median
level was 131 pg/ml (29–1235 pg/ml). In the patient
group, 69.3% of patients had serum VEGF levels
higher than the median level of the control group
which is 68.6 pg/ml. There were no significant
association between serum VEGF levels and histo-
pathological type of tumor (P40:05).
Serum VEGF levels and survival
Eight patients in the study group were lost to follow
up. Remaining 67 patients had median survival of
210 days (30–220þ days) (þ , shows that patient
still lives). When the study was finished, four
patients were still alive.
In the operable group (22 patients), median
survival was 225 days (30–540þ ) while in the
inoperable group 210 days (60–660 days).
We have found moderate negative correlation
between serum VEGF levels and survival (Spear-
man’s correlation coefficient ðrÞ ¼ 0:46; Po0:001)
(Fig. 2).
According to Cox regression analysis, serum VEGF
level was found to be a risk factor on the survival
independent of the T factor (relative risk¼ 1.78,
95% CI¼ 1.027–3.084, P ¼ 0:04).
Discussion
NSCLC is a lung cancer subgroup of particular
interest for its histopathological classification and
behaviour.7 More than half of the patients relapse
after complete resection, and this high recurrence
rate is attributable to microscopic metastases
present at the time of initial diagnosis.9 This high
metastatic potential of NSCLC may be due to
angiogenesis of tumor in which VEGF plays an
important role.
In our patient group, we found higher serum
VEGF levels compared to the healthy controls and
these high levels were shown to be statistically
significant. Similar results were obtained in some
malignancies including lung cancer previously.8,9,13
In our study, like other similar studies, median
and mean VEGF levels had high standart deviations.
We think that the heterogenity of the NSCLC itself
and the difficulties in using serum VEGF as a
biological marker might be the underlying cause.
While there is an association between serum
VEGF and tumor staging in some studies,8,14 there
was no such association in others.9,13 In our study
group, the distribution of patients according to
tumor staging was not homogenous. Thus, patients
were grouped according to the preferred therapy as
operable and inoperable. Although we could not
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Figure 2 Kaplan–Meier survival curve according to
median VEGF levels of 67 patients.
Figure 1 Distribution of median serum VEGF levels
between operable and inoperable groups.
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show a significant association between tumor
stages (each N, M) according to TNM staging
system, and serum VEGF levels; there was signifi-
cant difference between operable and inoperable
group by means of serum VEGF levels (P ¼ 0:031).
There are several hypothesises for the origin of
VEGF in serum. In our study, we showed that serum
VEGF levels for T1-2 patients (29 patients, 38.73%)
were higher than the T3-4 (46 patients, 61.3%)
ones. This finding was consistent with the previous
studies indicating a positive correlation between
serum VEGF levels and the primary tumor size. Also
this finding supports the hypothesis that tumoral
cells themselves are the main source of VEGF and
primary tumor size is important in detecting the
serum VEGF levels.12
There was no association between serum VEGF
levels and histological types of NSCLC in our study,
as none of the previous studies have shown
any.8,9,13
Limited data is available on the prognostic
significance of serum or plasma VEGF levels in
NSCLC. In various solid tumors, immunohistochem-
istry or ELISA is commonly used for prognostic
significance of VEGF. Especially in some hematolo-
gical malignancies, it has been documented that
VEGF overexpression is together with early relapse
and poor prognosis.10,12 But in majority of studies
concerning lung cancer, no prognostic significance
of serum VEGF on survival has been shown.
Decaussin et al.15 have measured the microvessel
density (MVD) and VEGF expression on the tumoral
tissue specimen of 69 Stage I-II NSCLC patients and
they were not able to demonstrate the effect of
MVD or VEGF expression on prognosis. However, in
our study, it is shown that survival of patients with
serum VEGF lower than 119 pg/ml is longer than the
patients with high serum VEGF levels. We think that
this result is due to our larger patient group.
In conclusion, we have demonstrated that serum
VEGF levels are higher as the tumor stage pro-
gresses and tumor size increases, so naturally we
had lower serum VEGF levels in the operable
patient group. We think that, in operable NSCLC
patients who has high serum VEGF levels, neutro-
lizing antibodies targetted against VEGF together
with adjuvant chemotherapy prior to surgery may
increase survival and better prognostic outcomes
might be achieved.
References
1. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial
growth factor and other biological predictors related to the
postoperative survival rate on non-small cell lung cancer.
Lung Cancer 2001;33(2–3):125–32.
2. Yamamato Y, Masakazu T, Kondo S, et al. Concentrations of
vascular endothelial growth factor in the sera of normal
controls and cancer patients. Clinl Cancer Res 1996;2:821–6.
3. Laack E, Kohler A, Kugler C, et al. Pretreatment serum levels
of matrix metalloproteinase-9 and vascular endothelial
growth factor in non-small-cell lungcancer. Ann Oncol
2002;13(10):1550–7.
4. Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth
factor in the serum of patients with non-small cell lung
cancer: correlation with platelet and leukocyte counts. Lung
Cancer 2001;33(2–3):171–9.
5. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial
growth factor is associated with neovascularization and
influences progression of non-small cell lung carcinoma. Clin
Cancer Res 1997;3(6):861–5.
6. Ferrara N. Vascular Endothelial Growth Factor. Eur J Cancer
1996;14:2413–22.
7. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and
p53 protein in lung cancer: their prognostic role and their
relation with vascular endothelial growth factor (VEGF)
expression. Br J Cancer 1997;75(9):1295–301.
8. Ohta Y, Watanabe Y, Murakami S, et al. Vascular endothelial
growth factor and lymph node metastasis in primary lung
cancer. Br J Cancer 1997;76(8):1041–5.
9. Brattstrom D, Bergqvist M, Hesselius P, et al. Elevated
preoperative serum levels of angiogenic cytokines correlate
to larger primary tumours and poorer survival in non-small
cell lung cancer patients. Lung Cancer 2002;37(1):57–63.
10. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of
vascular endothelial growth factor in the sera of normal
controls and cancer patients. Clin Cancer Res 1996;
2(5):821–6.
11. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms
of metastasis. Cancer 1997;15,80(8 Suppl.): 1529–1537.
12. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial
growth factor in the sera and effusions of patients with
malignant and nonmalignant disease. Cancer 1999;85(1):
178–87.
13. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K.
Elevated vascular endothelial growth factor levels in sera of
patients with lung cancer. Anticancer Res 1998;18(2B):
1251–4.
14. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K.
Vascular endothelial growth factor expression in non-small-
cell lung cancer: prognostic significance in squamous cell
carcinoma. J Thorac Cardiovasc Surg 1998 (May); 115(5):
1007–1014.
15. Decaussin M, Sartelet H, Robert C, et al. Expression of
vascular endothelial growth factor (VEGF) and its two
receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-
small cell lung carcinomas (NSCLCs): correlation with
angiogenesis and survival. J Pathol 1999;188(4):369–77.
ARTICLE IN PRESS
636 A. Kaya et al.
